No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GRAL240719C15000
- 1.90
- -3.64-65.70%
15min DelayClose Jul 18 15:59 ET
2.00High1.70Low
2.00Open5.54Pre Close3 Volume70 Open Interest15.00Strike Price560.00Turnover109.62%IV-0.12%PremiumJul 19, 2024Expiry Date1.92Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9897Delta0.0308Gamma8.79Leverage Ratio-0.0151Theta0.0003Rho8.70Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Express News | GRAIL Shares Are Trading Lower. The Company Announced That the First Participant Has Been Enrolled in the REACH/Galleri-Medicare Study at Community Health Network
Express News | Grail Inc - Medicare to Cover Costs for Galleri Study Participants
Express News | Grail Announces First Participant Enrolled in Reach Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (Mced) Test in the Medicare Population
Dow, S&P 500 Hit Closing Records as Markets Weigh Retail Sales Report, Earnings
The Dow Jones Industrial Average and the S&P 500 closed at all-time highs Tuesday as markets assessed official retail sales data for June and the latest corporate earnings.The Dow jumped 1.9% to 40,95
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
Express News | GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test
Comments
$Grail(GRAL.US$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
1
$Illumina(ILMN.US$ botched the acquisition of $Grail(GRAL.US$ after the move was banned by european authorities and has finished divesting as GRAL just opened shop on stock markets very recently as a separate entity from ILMN. with this shareholders might start to pour money back into Illumina which is clearly undervalued by any metric you throw at it it's not a dead business so there's some money to be made here you can look at the chart recently ...
5
$Grail(GRAL.US$ why circuit breaker?
Read more